Objective To explore the influencing mechanism of Zhengan Xifeng Decoction on blood pressure and gastrointestinal motility in SHR. Methods After 15 WKY and 90 SHR rats were were randomly divided into normal control group, model group, Benner Pury group, amlodipine group, Zhengan Xifeng Decoction high, middle, and low dose groups. The normal control group and model group were fed with distilled water daily. Rats in treatment group were administered with corresponding drugs daily. Blood pressure, gastric residual and intestinal propulsive ratio of rats was detected after eight-week intervention. Results Compared with the blank control group, systolic pressure, diastolic pressure, and mean arterial pressure were significantly higher than WKY rats of same age (P<0.05). Compared with the model group, the systolic pressure, diastolic pressure, and mean arterial pressure of treatment groups were significantly reduced (P<0.05). Compared with the blank control group, gastric residual rate of rats in the model group significantly decreased (P<0.05). Compared with the model group, the gastric residual rate in Zhengan Xifeng high dose group increased significantly, and intestinal propulsive ratio significantly increased (P<0.05), without statistical significance in the other treatment groups. Conclusion Zhengan Xifeng Decoction can reduce blood pressure in SHR, and regulate gastrointestinal motility.

Objective To probe the effects of dosages of aripiprazole on cognitive function of stabilized schizophrenic outpatients treated with risperidone. Methods A totol of 43 stabilized schizophrenic outpatients received risperidone were randomly divided into two groups. Aripiprazole added to control group (n=22)was taken by (20~30)mg/d and the study group(n=21)did by (5~15) mg/d,respectively, for 12 weeks. Brief Assessment of Cognition in Schizophrenia (BACS,Chinese edition)and Positive and Negative Syndrome Scale (PANSS)were used to evaluate efficacy. Treatment Emergent Symptom Scale (TESS) was used to evaluate adverse effects during this trial. Results The occurring rates of adverse effects for the two groups were not significantly different (P>0.05). Risperidone augmentation with aripiprazole by(5~15)mg/d significantly improved partial cognitive function and negative symptoms for these patients. Add-on treat-ment with aripiprazole by (20~30) mg/d significantly impair working memory(WM) and executive function (EF) (P<0.01), although that significantly improved motor speed (MS) and negative symptoms as the former did. Conclusion Risperidone augmentation with a lower rather than higher dosage of aripiprazole would improve cognitive function most favorably. These findings need further substantial and long-term trials to be established .